Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02457195 · ClinicalTrials.gov registry record · Phase 2
Granisetron Transdermal Patch for Prevention of Postoperative Nausea and Vomiting
A Phase 2 study, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT02457195 is a Phase 2 study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 50 participants.
The verdict
NCT02457195, a Phase 2 study, has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate the efficacy and safety of adding transdermal preparation of granisetron (Sancuso ®) to the current postoperative nausea and vomiting (PONV) standard prophylaxis regimen with dexamethasone and ondansetron in patients with the previous history of severe, particularly delayed and/or post-discharge, PONV and undergoing surgical procedure under general anesthesia. The specific aims of the study include: 1. efficacy of the investigated therapy in prevention of PONV up to 120 hours after surgery 2. incidence and seriousness of the observed side effects 3. ability of patients to self-administer preoperatively and maintain the investigated patch during the perioperative period 4. level of satisfaction with the preoperative PONV prophylaxis.
Interventions
- DRUG granisetron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2016-02 |
| Est. Completion | 2018-02-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02457195
The ClinicalTrials.gov registry entry for NCT02457195 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which granisetron is the first listed.
NCT02457195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02457195 about?
NCT02457195 is a clinical study titled "Granisetron Transdermal Patch for Prevention of Postoperative Nausea and Vomiting". The objective of the study is to evaluate the efficacy and safety of adding transdermal preparation of granisetron (Sancuso ®) to the current postoperative nausea and vomiting (PONV) standard prophylaxis regimen with dexamethasone and ondansetron in patients with the previous history of severe, part...
What is the current status of trial NCT02457195?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2016-02. Estimated completion is 2018-02-19.
What interventions are being tested in trial NCT02457195?
The interventions under investigation include: granisetron (DRUG).
Who is sponsoring clinical trial NCT02457195?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.